



FFB 16 2006

**SUBMISSION UNDER MPEP 609 D**

Page 1 of 2

<b>SUBMISSION UNDER MPEP 609 D</b>	<b>Application Number</b>	<b>10/606,422</b>
	<b>Filing Date</b>	<b>June 26, 2003</b>
	<b>First Named Inventor</b>	<b>McComsey</b>
	<b>Group Art Unit</b>	<b>1653</b>
	<b>Examiner Name</b>	<b>LUKTON, DAVID</b>
<b>Page 1 of 2</b>	<b>Attorney Docket Number</b>	<b>ORT 1222(DIV)</b>

## **U.S. PATENT DOCUMENTS**

## **FOREIGN PATENT DOCUMENTS**

**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Examiner 's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
		LINDE ET AL, "Pharmacological treatment for prevention of restenosis" EXPERT OPINION, 2001, pp 281-302, ASHLEY PUBLICATIONS, WWW.ashley-pub.com, CANADA.	
		ISCHINGER, THOMAS, "Antithrombotics in Interventional Cardiology: Optimizing Treatment and Strategies", 1998, pp 25L-28L, VOL. 28 (5B), EXCERPTA MEDICA, INC., THE AMERICAN JOURNAL OF CARDIOLOGY.	
		SCHWARTZ, ROBERT, "Pathophysiology of Restenosis: Interaction of Thrombosis, Hyperplasia, and/or Remodeling", EXCERPTA MEDICA, INC., A SYMPOSIUM: INTERVENTIONAL VASCULAR MEDICINE, 1998, PP14E-17E.	
		MARX ET AL, "Rampamycin-FKBP Inhibits Cell Cycle Regulators of Proliferation in Vascular Smooth Muscle Cells" CIRCULATION RESEARCH, 1995 AMERICAN HEART ASSOCIATION, INC. 1995, VOL 76, pp 412-417.	
		SOLLOTT ET AL, "Taxol Inhibits Neointimal Smooth Muscle Cell Accumulation After Angioplasty In the Rat" THE JOURNAL OF CLINICAL INVESTIGATION, INC., APRIL 1995, pp1869-1876, THE JOURNAL OF CLINICAL INVESTIGATION, INC., VOL. 95, pp 1869-1876.	
		SUZUKI ET AL, "STENT-BASED DELIVERY OF SIROLIMUS REDUCES NEOINTIMAL FORMATION IN A PORCINE CORONARY MODEL" 2001 AMERICAN HEART ASSOCIATION, pp 1188-1193, USA.	
		ANDRADE-GORDON ET AL, "ADMINISTRATION OF A POTENT ANTAGONIST OF PROTEASE-ACTIVATED RECEPTOR-1 (PAR-1) ATTENUATES VASCULAR RESTENOSIS FOLLOWING BALLOON ANGIOPLASTY IN RATS". THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2001, 298: No. 1, pp 34-42, USA.	
		DERIAN, CLAUDIA ET AL, "BLOCKAGE OF THE THROMBIN RECEPTOR PROTEASE-ACTIVATED RECEPTOR-1 WITH A SMALL-MOLECULE ANTAGONIST PREVENTS THROMBUS FORMATION AND	

David Lakey 4-18-06

*DR*

X	(VASCULAR OCCLUSION IN NON-HUMAN PRIMATES" THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS" 2003, PP 855-861, vol. 304, THE AMERICAN SOCIETY OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS.	
<i>DL</i>	CHESEBRO ET AL, "ANTITHROMBOTIC THERAPY AND PROGRESSION OF CORONARY ARTERY DISEASE, ANTIPLATELET VS. ANTITHROMBINS", CIRCULATION, 1992, 86(suppl III): III-100-III-111	
<i>DL</i>	WHITE, HARVEY, "NEWER ANTIPLATELET AGENTS IN ACUTE CORONARY SYNDROMES" CARDIOLOGY DEPT. GREEN LANE HOSPITAL, NEW ZEALAND, e-mail: harveyw@ahsl.co.nz, 1999, MOSBY, INC..	
<i>DL</i>	VERSTRAETE ET AL, "NOVEL ANTITHROMBOTIC DRUGS IN DEVELOPMENT", CENTER FOR MOLECULAR AND VASCULAR BIOLOGY, UNIVERSITY OF LEUVEN, BELGIUM, DRUGS, 1995, pp 858-884, Adis International Limited.	
<i>DL</i>	WEKSLER, BABETTE, "ANTIPLATELET AGENTS IN STROKE PREVENTION" DEPT. OF MEDICINE, NEW YORK PRESBYTERIAN HOSPITAL-WELL CORNELL MEDICAL CENTER, NEW YORK, NY USA, 2000; 10(suppl 5) 41-48, www.karger.com/journals/ced.	
X	MOUSA, SHAKER, "ANTIPLATELET THERAPIES: FROM ASPIRIN TO GPIIb/IIIa-RECEPTOR ANTAGONISTS AND BEYOND" THERAPEUTIC FOCUS ELSEVIER SCIENCE LTD, 1999, PP 552-560, vol. 4, No. 12, USA.	

Examiner Signature	Date Considered
<i>David Lubbock</i>	9-18-06